(Q39672097)

13 September 2017

title

Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin (English)

1 reference

13 September 2017

Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin (English)

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

16 June 2024

1 reference

Jun Zou

1

1 reference

13 September 2017

Minfeng Gan

2

1 reference

13 September 2017

Nana Mao

3

1 reference

13 September 2017

Xuesong Zhu

4

1 reference

13 September 2017

Qin Shi

5

1 reference

13 September 2017

Huilin Yang

6

1 reference

13 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20682173

16 June 2024

publication date

1 April 2010

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S0188440910000974?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

https://api.elsevier.com/content/article/PII:S0188440910000974?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Archives of Medical Research

16 June 2024

published in

1 reference

13 September 2017

volume

41

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

162-169

1 reference

Survival from adolescent cancer.

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

16 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

16 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

16 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Gene therapy for osteosarcoma: steps towards clinical studies.

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

VEGF blockade decelerates the growth of a murine experimental osteosarcoma

16 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

The case for survivin as a regulator of microtubule dynamics and cell-death decisions

16 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis.

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

An IAP-IAP complex inhibits apoptosis

16 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Chromosome alignment and segregation regulated by ubiquitination of survivin

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Validating survivin as a cancer therapeutic target

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Expression of survivin and correlation with PCNA in osteosarcoma.

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Survivin as a prognostic factor for osteosarcoma patients

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Survivin expression in human osteosarcoma is a marker for survival

16 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers.

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Reversal of TNF-alpha resistance by hyperthermia: role of mitochondria.

16 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy

16 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo

16 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene

16 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells

16 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension

16 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma

16 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

Targeted manipulation of apoptosis in cancer treatment

16 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ARCMED.2010.04.006

16 June 2024

Identifiers

1 reference

13 September 2017

1 reference